DE69737736D1 - Induktion rev- und tat-spezifischer zytotoxischer t-zellen zur prävention und behandlung einer infektion durch humanen immundefizienz-virus (hiv) - Google Patents

Induktion rev- und tat-spezifischer zytotoxischer t-zellen zur prävention und behandlung einer infektion durch humanen immundefizienz-virus (hiv)

Info

Publication number
DE69737736D1
DE69737736D1 DE69737736T DE69737736T DE69737736D1 DE 69737736 D1 DE69737736 D1 DE 69737736D1 DE 69737736 T DE69737736 T DE 69737736T DE 69737736 T DE69737736 T DE 69737736T DE 69737736 D1 DE69737736 D1 DE 69737736D1
Authority
DE
Germany
Prior art keywords
rev
tat
cells
hiv
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69737736T
Other languages
English (en)
Inventor
Baalen Carel A Van
Albertus D M E Osterhaus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Erasmus Universiteit Rotterdam
Original Assignee
Erasmus Universiteit Rotterdam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erasmus Universiteit Rotterdam filed Critical Erasmus Universiteit Rotterdam
Application granted granted Critical
Publication of DE69737736D1 publication Critical patent/DE69737736D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE69737736T 1996-10-18 1997-10-17 Induktion rev- und tat-spezifischer zytotoxischer t-zellen zur prävention und behandlung einer infektion durch humanen immundefizienz-virus (hiv) Expired - Lifetime DE69737736D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/733,789 US6024965A (en) 1996-10-18 1996-10-18 Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection
PCT/IB1997/001402 WO1998017309A1 (en) 1996-10-18 1997-10-17 Induction of rev and tat specific cytotoxic t-cells for prevention and treatment of human immunodeficiency virus (hiv) infection

Publications (1)

Publication Number Publication Date
DE69737736D1 true DE69737736D1 (de) 2007-06-28

Family

ID=24949122

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69737736T Expired - Lifetime DE69737736D1 (de) 1996-10-18 1997-10-17 Induktion rev- und tat-spezifischer zytotoxischer t-zellen zur prävention und behandlung einer infektion durch humanen immundefizienz-virus (hiv)

Country Status (10)

Country Link
US (3) US6024965A (de)
EP (1) EP0930894B1 (de)
JP (2) JP2001504812A (de)
KR (1) KR20000052649A (de)
AT (1) ATE362379T1 (de)
AU (1) AU730887B2 (de)
CA (1) CA2268720A1 (de)
DE (1) DE69737736D1 (de)
NZ (1) NZ335612A (de)
WO (1) WO1998017309A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
IT1297090B1 (it) * 1997-12-01 1999-08-03 Barbara Ensoli Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le
US7105164B1 (en) * 1998-04-07 2006-09-12 Sanofi Pasteur Limited HIV-specific cytotoxic T-cell responses
US20010019714A1 (en) * 1998-04-07 2001-09-06 Charles D. Y. Sia Hiv-specific cytotoxic t-cell responses
US20010008627A1 (en) * 1999-01-22 2001-07-19 Soll David R. Hiv-encoded chemoattractant
CA2767116A1 (en) 1999-05-13 2000-11-23 Wyeth Holdings Corporation Adjuvant combination formulations
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
JP2003510094A (ja) 1999-09-08 2003-03-18 トランジェーヌ、ソシエテ、アノニム Ｍｕｃ−１由来のペプチド
US6399067B1 (en) * 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
WO2005090392A1 (en) * 2004-03-16 2005-09-29 Inist Inc. Tat-based tolerogen compositions and methods of making and using same
DE10053781B4 (de) * 2000-10-30 2008-07-03 Geneart Ag Kernexportreportersystem
US20020107193A1 (en) * 2000-11-09 2002-08-08 Glazner Gordon W. Therapeutic uses for IP3 receptor-mediated calcium channel modulators
IL155690A0 (en) 2000-11-10 2003-11-23 Wyeth Corp Adjuvant combination formulations
GB0323840D0 (en) * 2003-10-10 2003-11-12 Ist Superiore Sanita Vaccines
US20050208482A1 (en) * 2004-03-16 2005-09-22 Cohen David I Tat-based immunomodulatory compositions and methods for their discovery and use
EP1851247A2 (de) 2005-02-15 2007-11-07 Thymon L.L.C. Verfahren und zusammensetzungen zur behinderung der vervielfältigung von hiv-1
US7455249B2 (en) * 2006-03-28 2008-11-25 Illinois Tool Works Inc. Combined direct and indirect charging system for electrostatically-aided coating system
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
CA2755897C (en) 2009-03-23 2020-01-28 Nanirx, Inc. Treatment of cancers with immunostimulatory hiv tat derivative polypeptides
GB201004656D0 (en) * 2010-03-19 2010-05-05 Ensoli Barbara Immune therapy
EP2550362B1 (de) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv-glycoproteine und rekombinante vektoren
US8486717B2 (en) 2011-01-18 2013-07-16 Symbolics, Llc Lateral flow assays using two dimensional features
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
WO2015051245A1 (en) 2013-10-04 2015-04-09 Pin Pharma, Inc. Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
US5336758A (en) * 1990-03-09 1994-08-09 The United States Of America As Represented By The Department Of Health And Human Services Peptides stimulating cytotoxic T cells immune to HIV RT
WO1994015634A1 (en) * 1992-12-30 1994-07-21 Matthias Rath Tat and rev oligopeptides in hiv treatment

Also Published As

Publication number Publication date
CA2268720A1 (en) 1998-04-30
EP0930894B1 (de) 2007-05-16
US6319666B1 (en) 2001-11-20
JP2001504812A (ja) 2001-04-10
AU730887B2 (en) 2001-03-15
JP2006265255A (ja) 2006-10-05
NZ335612A (en) 2000-10-27
ATE362379T1 (de) 2007-06-15
US6024965A (en) 2000-02-15
WO1998017309A1 (en) 1998-04-30
AU4719597A (en) 1998-05-15
KR20000052649A (ko) 2000-08-25
EP0930894A1 (de) 1999-07-28
US5942401A (en) 1999-08-24

Similar Documents

Publication Publication Date Title
DE69737736D1 (de) Induktion rev- und tat-spezifischer zytotoxischer t-zellen zur prävention und behandlung einer infektion durch humanen immundefizienz-virus (hiv)
Nara et al. Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses
Krowka et al. Lymphocyte proliferative responses to human immunodeficiency virus antigens in vitro.
DE69535757D1 (de) Rekombinanter immunschwächepoxvirus
ES2016426A6 (es) Un procedimiento para detectar la presencia de anticuerpos frente a virus del sida en el suero humano.
DK33190A (da) Hiv-3 retrovirus og anvendelse heraf
ES8705522A1 (es) Un procedimiento para la preparacion de derivados purificados de una glicoproteina.
ATE418562T1 (de) Ctl epitope des epstein-barr virus
ATE264914T1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
HK1044778A1 (en) Hiv-peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv hiv
NO863803L (no) Vaksiner og immunoanalyser for ervervet immunsviktsyndrom (aids).
BR0114036A (pt) Peptìdeos de hiv, antìgenos, composições de vacina, kit de imunoensaio e um método para detectar anticorpos induzidos pelo hiv
DE60023300D1 (de) Verwendung von cpg als adjuvans für hivimpstoff
HUP0202502A2 (hu) Virális fertőzőképességet blokkoló peptidek és eljárások ezek alkalmazására
DK0541692T3 (da) Herpes simplex virus VP-16-vacciner
Shugars et al. Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lymphocytotropic strains of human immunodeficiency virus type 1
ATE355375T1 (de) Bakterioferritin aus helicobacter pylori
BR0114046A (pt) Peptìdeos reguladores e auxiliares de hiv, antìgenos, composições de vacinas, kit de imunoensaio e um método para detectar anticorpos induzidos por hiv
HUP0105070A2 (hu) Hepatitis B vírus fertőzések megelőzésére és kezelésére szolgáló készlet
WO2002020571A3 (en) Attenuated hiv strains and use thereof
DE69633919D1 (de) Mehrzweckvakzine gegen umhüllte viren
DK76688A (da) Vaccine indeholdende f-proteinet fra aids-virus
FR2868318B1 (fr) Antigene tat stabilise et ses applications pour la vaccination anti-vih
DE60024259D1 (de) Trennung eines humanen retrovirus
ATE284709T1 (de) Virale chimären aus caev und hiv-1 genetischen elementen

Legal Events

Date Code Title Description
8332 No legal effect for de